Impact of breast cancer subtype on clinical outcomes after Gamma Knife radiosurgery for brain metastases from breast cancer: a multi-institutional retrospective study (JLGK1702)
Authors:
- 1 August 2020
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 184 (1) , 149-159
Abstract
Introduction Brain metastasis (BM) is one of the most important issues in the management of breast cancer (BC), since BMs are associated with neurological deficits. However, the importance of BC subtypes remains unclear for BM treated with Gamma Knife radiosurgery (GKS). Thus, we conducted a multicenter retrospective study to compare clinical outcomes based on BC subtypes, with the aim of developing an optimal treatment strategy. Methods We studied 439 patients with breast cancer and 1–10 BM from 16 GKS facilities in Japan. Overall survival (OS) was analyzed by the Kaplan–Meier method, and cumulative incidences of systemic death (SD), neurologic death (ND), and tumor progression were estimated by competing risk analysis. Results OS differed among subtypes. The median OS time (months) after GKS was 10.4 in triple-negative (TN), 13.7 in Luminal, 31.4 in HER2, and 35.8 in Luminal-HER2 subtype BC (p < 0.0001). On multivariate analysis, poor control of the primary disease (hazard ratio [HR] = 1.84, p < 0.0001), active extracranial disease (HR = 2.76, p < 0.0001), neurological symptoms (HR 1.44, p = 0.01), and HER2 negativity (HR = 2.66, p < 0.0001) were significantly associated with worse OS. HER2 positivity was an independent risk factor for local recurrence (p = 0.03) but associated with lower rates of ND (p = 0.03). TN histology was associated with higher rates of distant brain failure (p = 0.03). Conclusions HER2 positivity is related to the longer OS after SRS; however, we should pay attention to preventing recurrence in Luminal-HER2 patients. Also, TN patients require meticulous follow-up observation to detect distant metastases and/or LMD.Keywords
Funding Information
- Elekta
This publication has 36 references indexed in Scilit:
- Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapiesCancer, 2017
- Brain metastasis in breast cancer: a comprehensive literature reviewJournal of Neuro-Oncology, 2016
- Breast Cancer Subtypes Predispose the Site of Distant MetastasesAmerican Journal of Clinical Pathology, 2015
- Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysisBreast Cancer Research and Treatment, 2014
- Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Metastatic Behavior of Breast Cancer SubtypesJournal of Clinical Oncology, 2010
- Extended Survival in Women With Brain Metastases From HER2 Overexpressing Breast CancerAmerican Journal of Clinical Oncology, 2008
- Defining prognosis for women with breast cancer and CNS metastases by HER2 statusAnnals of Oncology, 2008
- Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancerJournal of Neuro-Oncology, 2007
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003